BioPharm America™ 2009, BioJapan 2009, and BIO-Europe 2009
M's Science attends the BioPharm America™ 2009, BioJapan 2009, and BIO-Europe 2009 partnering conferences. Please note that M's Science will present its programs at BIO-Europe 2009. We are interested in discussing partnering opportunities with you and look forward to meeting with you at these conferences.
M's Science seeks licensees and /
or collaboration partners for its HF10 and MC116 series program.
Please follow the links below for more detailed information on these programs.
 MC116 series non-confidential summary 2009
HF10 non-confidential summary 2009
M's Science Corporation
M's Science Corporation - A Japanese biopharma company with international focus
"Executive Summary"
- Company founded in November 2000 and headquartered in Kobe, Japan
- Focus on international clinical development of CNS and cancer therapeutics with novel mechanisms of action
- Completed two Phase 2a trials in Europe with the CNS compound SA4503 in depression and stroke recovery
- Initiated Phase 1/2 trial in the United States with the cancer therapeutics HF10
- Novel series of CNS active compounds in preclinical development for treatment of Parkinson's Disease, Alzheimer's Disease and cognitive impairment in schizophrenia
- Raised approximately 48 Mio US$ in venture capital since inception
- Senior management team with international experience in drug discovery, development and commercialization
- In-house R&D capabilities to rapidly identify and develop novel CNS therapeutics
1.) Corporate information
M's Science is headquartered in Kobe, Japan, and conducts the clinical development of its compounds in Europe and the United States. Since its inception in November 2000 the company has raised approximately 48 Mio US$ from Japanese venture capital groups. The company was able to attract a senior management team of pharmaceutical and biotech company executives with international experience in drug discovery, development and commercialization. M's Science combines its in-house experience and capabilities with extensive outsourcing of drug discovery and development activities to rapidly progress compounds with novel mechanisms of action from inception to the clinic.
2.) SA4503 - A CNS therapeutic compound with unique profile
SA4503 is a potent and selective agonist of the sigma-1 receptor. SA4503 enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. In addition, SA4503 has neuromodulatory and cognitive enhancer activities. SA4503 offers thus a unique opportunity towards the therapy of various CNS disorders. M's Science initially focuses its clinical development of SA4503 on the enhancement of recovery from stroke and on the treatment of major depressive disorder (MDD). Two Phase 2 studies for MDD and stroke recovery have been completed in Europe. Moreover, due to its cognition enhancing activities, SA4503 has potential as a drug to treat Alzheimer's disease.
3.) HF10 - An oncolytic herpes simplex virus
HF10 is a natural isolate of an attenuated herpes simplex virus and possesses strong tumor killing ability (oncolytic virus). HF10's activity in patients with breast or head & neck cancer has been demonstrated in studies conducted in collaboration with the University of Nagoya. M's Science initially develops HF10 for the treatment of head & neck cancer and intends to expand this program to the therapy of other cancers. A Phase 1/2 clinical study is on-going in the United States.
4.) MC116 series - Novel sigma-1 receptor agonists for treatment of CNS disorders
This program represents a compound family with novel mechanism of action and internationally filed composition of matter patent applications. MC116 is the lead molecule of this series and has potent sigma-1 receptor activity. Compounds of this series display cellular activity in assays of neuroregeneration, neuroprotection and neurotransmission. MC116 and related compounds display excellent oral availability and CNS penetration, and an absence of toxicity in a 15 day repeat administration study. Finally, these compounds display in vivo activity in a model of cognitive impairment after acute and chronic dosing. The mechanism of action of these compounds suggests many potential CNS indications including Parkinson's Disease, Alzheimer's Disease and cognitive impairment in schizophrenia. Process development and IND enabling studies were initiated with an anticipated IND filing in late 2010.
Contacts:
Mr. Akihiko Shimauchi, President & Representative Director
ashimauchi@m-sci.com
Phone: +81 78 388 6000
Dr. Roman Urfer, Chief Scientific Officer & Senior Vice President International Development
roman.urfer@ms-science.com
Phone +1 650 784 6008
M's Science Corporation, Kobe International Business Center 5F, 5-5-2, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan
|
